Wechselwirkungen · Relistor
Relistor 8 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 15
HOS-209261 · Präparat HOS-154281
Methylnaltrexone bromide does not affect the pharmacokinetics of medicinal products metabolised by cytochrome P450 (CYP) isozymes. Methylnaltrexone bromide is minimally metabolised by CYP isozymes. In vitro metabolism studies suggest that methylnaltrexone bromide does not inhibit the activity of CYP1A2, CYP2E1, CYP2B6, CYP2A6, CYP2C9, CYP2C19 or CYP3A4, while it is a weak inhibitor of the metabolism of a model CYP2D6 substrate. In a clinical drug interaction study in healthy adult male subjects, a subcutaneous dose of 0.3 mg/kg of methylnaltrexone bromide did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dextromethorphan (HOS-109265)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-24T12:28:00Z · SHA-256 ddca5ca993d5966efb987ce83c30cb95ab0637c0d1e42cad8626d186bb49de0f · Passage 3d41252716184fce3b7f50973edcb5df879f50c8ed4b2e0117b6138278ae159b · Zeichen 0–646 im Abschnitt